中期因子与慢性肾脏病相关多系统器官功能障碍
慢性肾脏病(CKD)是多系统进展性疾病,机制驱动因素未明。本综述汇总临床前证据,提示结合肝素/内皮糖萼的分子中期因子(MK)在CKD进展、高血压、血管和心脏疾病、骨病及CKD相关癌症中具病理作用,且CKD患者循环和尿MK随GFR下降而升高。
要点
- MK在CKD相关多器官病变中具潜在病理作用。
- CKD患者循环和尿MK水平随GFR下降而升高。
- 给予可溶性MK可逆转MK缺陷的保护效应。
核心结论
- 不断增多的证据支持MK可能驱动CKD相关多系统疾病,并具治疗靶点潜力。
研究设计与样本
- 综述汇总临床前与临床观察证据,涉及MK与内皮糖萼关系及CKD患者MK水平和糖萼谱改变。
主要发现
- 临床前证据提示MK在CKD进展、高血压、血管和心脏疾病、骨病及CKD相关癌症中具病理作用。
- CKD患者循环和尿MK升高与GFR丢失成比例。
- 实验性肾病中给予可溶性MK可逆转MK缺陷的保护效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic kidney disease (CKD) is a progressive multisystem condition with yet undefined mechanistic drivers and multiple implicated soluble factors. If identified, these factors could be targeted for therapeutic intervention for a disease that currently lacks specific treatment. There is increasing preclinical evidence that the heparin/endothelial glycocalyx-binding molecule midkine (MK) has a pathological role in multiple CKD-related, organ-specific disease processes, including CKD progression, hypertension, vascular and cardiac disease, bone disease and CKD-related cancers. Concurrent with this are studies documenting increases in circulating and urine MK proportional to glomerular filtration rate (GFR) loss in CKD patients and evidence that administering soluble MK reverses the protective effects of MK deficiency in experimental kidney disease. This review summarizes the growing body of evidence supporting MK's potential role in driving CKD-related multisystem disease, including MK's relationship with the endothelial glycocalyx, the deranged MK levels and glycocalyx profile in CKD patients and a proposed model of MK organ interplay in CKD disease processes and highlights the importance of ongoing research into MK's potential as a therapeutic target.
引用
- Campbell VK, Gately RP, Krishnasamy R, et al. Midkine and chronic kidney disease-associated multisystem organ dysfunctions. Nephrol Dial Transplant. 2021. PMID: 32542315. doi:10.1093/ndt/gfaa084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。